Stella, a US-based company involved in the delivery of high outcome treatments for emotional trauma and mental health management, announced on Wednesday that it has named Dr Pat Basu as the chairman of its board of directors.
Dr Basu is a veteran healthcare CEO, entrepreneur and former White House fellow. Presently, he serves as president and chief executive officer of Cancer Treatment Centers of America Global (CTCA). He is a business leader who has headed organisations in the public, private, non-profit and government sectors. He has managed organisations which collectively have delivered care or managed care for more than 25 million Americans per annum. He has served as a member of the Executive Leadership Team of UnitedHealth Group, president of OptumCare, partner-level positions at private equity firm Chicago Pacific Founders, operating partner of P3 Health Partners, and venture capital firm Pritzker Group Venture Capital. He has founded Doctor On Demand. He has served as a president, chief operating officer and chief medical officer at vRad. He serves on the board of directors for the Chicago Museum of Science and Industry and the Morton Arboretum. He has served as the founding faculty director of Health Policy and Finance at Stanford University. He has served on the Illinois State Board of Health, the Illinois Institute of Government & Public Affairs, Leadership Greater Chicago Daniel Burnham Fellow, the board of directors for the University of Illinois, and Stanford Medical Alumni Association, and has been a member of the Council on Foreign Relations.
Stella CEO, Philippe Sanchez, said, 'We are pleased that Dr Pat Basu has joined Stella's board, as our interests and mission have aligned to heal those experiencing devastating and lasting traumas of disease, cancer, and other life events. We hope to extend our network and make lasting impacts possible for those suffering.'
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business